Efficacy and safety of switching from Eculizumab to Ravulizumab for the maintenance of aHUS remission after kidney transplant: a preliminary experience.

IF 2.7 4区医学 Q2 UROLOGY & NEPHROLOGY

Journal of Nephrology Pub Date : 2024-07-16 DOI:10.1007/s40620-024-02005-7

Marco Busutti, Federica Maritati, Greta Borelli, Claudia Bini, Valeria Corradetti, Vania Cuna, Chiara Abenavoli, Michele Provenzano, Matteo Ravaioli, Gaetano La Manna, Giorgia Comai

引用次数: 0

查看原文本刊更多论文

肾移植术后将Eculizumab换成Ravulizumab以维持aHUS缓解的有效性和安全性：初步经验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nephrology 医学-泌尿学与肾脏学

CiteScore

5.60

自引率

5.90%

发文量

289

审稿时长

3-8 weeks

期刊介绍： Journal of Nephrology is a bimonthly journal that considers publication of peer reviewed original manuscripts dealing with both clinical and laboratory investigations of relevance to the broad fields of Nephrology, Dialysis and Transplantation. It is the Official Journal of the Italian Society of Nephrology (SIN).